
Year
DEALS // DEV.
Country
Therapeutic Area
Study Phase
Deal Type
Product Type
Dosage Form
Lead Product
Target

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Study Phase : Phase I/ Phase II
Recipient : Alzamend Neuro
Deal Size : Inapplicable
Deal Type : Inapplicable
Study in Subjects With Mild-to-Moderate Alzheimer's Dementia
Details : ALZN002 is a Vaccine drug candidate, which is currently being evaluated in phase I/ phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Inapplicable
April 28, 2023
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Highest Development Status : Phase I/ Phase II
Recipient : Alzamend Neuro
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Study Phase : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership
Details : ALZN002 is a proprietary active immunotherapy product. It consists of autologous DCs, which are activated WBCs taken from each individual patient that are then engineered outside of the body to attack Alzheimer’s-related amyloid-beta proteins.
Product Name : Undisclosed
Product Type : Vaccine
Upfront Cash : Undisclosed
January 04, 2023
Lead Product(s) : ALZN002
Therapeutic Area : Neurology
Highest Development Status : IND Enabling
Recipient : Alzamend Neuro
Deal Size : Undisclosed
Deal Type : Partnership

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Lomecel-B, an allogeneic medicinal signaling cell (MSC) therapy product isolated from the bone marrow of adult donors. Longeveron is advancing Lomecel-B through clinical trials in 3 indications: Hypoplastic Left Heart Syndrome, Alzheimer’s Disease, and...
Product Name : Lomecel-B
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 10, 2022
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable
Citius Pharmaceuticals to Accelerate Phase 3 Mino-Lok Trial by Expanding Trial Sites Internationally
Details : Mino-Lok (minocycline) is an antibiotic lock solution used to treat patients with catheter-related bloodstream infections (CRBSIs) and central line associated bloodstream infections (CLABSIs).
Product Name : Mino-Lok
Product Type : Miscellaneous
Upfront Cash : Inapplicable
May 06, 2022
Lead Product(s) : Minocycline Hydrochloride,Ethanol,Edetate Calcium Disodium
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Sponsor : Citius Pharmaceuticals
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : JadiCell (mesenchymal stem cells), was shown to be 100% effective in saving the lives of COVID-19 patients under age of 85 in a double-blind, randomized, placebo controlled clinical trial with patients in the ICU on a ventilator.
Product Name : JadiCell
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
May 02, 2022
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : The unprecedented results from JadiCells allowed for 100% patient survival at one month in subjects treated who were less than 85 years old, and 91% survival in subjects of all ages, compared to 42% survival in the control group.
Product Name : JadiCell
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 28, 2022
Lead Product(s) : Allogeneic Umbilical Cord Mesenchymal Stem Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase III
Recipient : Therapeutic Solutions
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Neurology
Study Phase : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Lomecel-B Effects on Alzheimer's Disease
Details : Allogeneic Mesenchymal Stem Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Alzheimer Disease.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
February 10, 2022
Lead Product(s) : Allogeneic Mesenchymal Stem Cell
Therapeutic Area : Neurology
Highest Development Status : Phase II
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Rifaximin
Therapeutic Area : Dermatology
Study Phase : Phase II
Recipient : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable
Details : Rifaximin is a Antibiotic drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of Rosacea.
Product Name : Undisclosed
Product Type : Antibiotic
Upfront Cash : Inapplicable
December 09, 2021
Lead Product(s) : Rifaximin
Therapeutic Area : Dermatology
Highest Development Status : Phase II
Recipient : Alfasigma
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Study Phase : Phase I
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable
Longeveron Selects Clinical Research Organization for Phase 2 Alzheimer’s Disease Trial
Details : LOMECEL-B™ cell-based therapy product (“Lomecel-B”), which is derived from culture-expanded medicinal signaling cells (MSCs) that are sourced from bone marrow of young, healthy adult donors.
Product Name : Lomecel-B
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
November 05, 2021
Lead Product(s) : Laromestrocel
Therapeutic Area : Neurology
Highest Development Status : Phase I
Recipient : Longeveron
Deal Size : Inapplicable
Deal Type : Inapplicable

Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass.
Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.
Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell
Therapeutic Area : Infections and Infectious Diseases
Study Phase : Phase II
Recipient : Stemedica Cell Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
A Phase II Study in Patients With Moderate to Severe ARDS Due to COVID-19
Details : Allogeneic Mesenchymal Bone Marrow Cell is a Cell and Gene Therapy drug candidate, which is currently being evaluated in phase II clinical studies for the treatment of COVID-19.
Product Name : Undisclosed
Product Type : Cell & Gene Therapy
Upfront Cash : Inapplicable
March 03, 2021
Lead Product(s) : Allogeneic Mesenchymal Bone Marrow Cell
Therapeutic Area : Infections and Infectious Diseases
Highest Development Status : Phase II
Recipient : Stemedica Cell Technologies
Deal Size : Inapplicable
Deal Type : Inapplicable
